Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly’s Dosing Scheme For Donanemab In Alzheimer’s And Treatment Cost Effectiveness

Executive Summary

Firm’s aggressive approach to amyloid plaque removal means a shorter duration of treatment and potentially lower costs.

You may also be interested in...



CMS Expects 'Consistent' Coverage Of Amyloid PET Scans Even Without National Standard

Medicare has finally rescinded its 10-year-old national restrictions on covering the diagnostic now that advances in amyloid plaque-removing drugs have underscored the importance of PET scans.

Medicare Coverage Of Amyloid PET Scans In Alzheimer’s Expected To Be ‘Consistent,’ Even Without National Standard, CMS Says

Medicare has finally rescinded its 10-year-old national restrictions on covering the diagnostic now that advances in amyloid plaque-removing drugs have underscored the importance of PET scans.

Lilly’s Donanemab, Now At FDA, Poised To Join Alzheimer’s Armamentarium

Lilly expects US approval of the anti-amyloid therapy by the end of the year. Full Phase III data were detailed at AAIC.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel